Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 8%
Hold 67%
Sell 25%
Strong Sell 0%

Bulls say

Moderna is a biotech company that has a strong outlook due to its successful mRNA technology, which was validated by its rapid development of a COVID-19 vaccine. With a wide range of clinical studies in various therapeutic areas, including oncology and cardiovascular disease, and a strong focus on personalized medicine, the company is poised for future growth. Moderna also has a solid financial position, with projected product sales of $1.73 billion in 2025 that could potentially reach $3.5 billion by 2028. Additionally, the company has a diverse workforce, with 50% female employees and a good representation of different racial and ethnic backgrounds.

Bears say

Moderna is a relatively young company, with only a decade of operations and an IPO less than three years ago. While the COVID vaccine was a major success, there are significant risks associated with clinical trials and regulatory approval for their 35 mRNA development candidates. Their growth plans are optimistic and heavily dependent on future product sales, and the recent failure of the CMV vaccine has resulted in a significant reduction in their overall value. This, coupled with relatively early-stage programs in rare diseases, make Moderna's stock a high-risk investment.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 8% recommend Buy, 67% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.